Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
   Or select

Or become a subscriber

Click here to view
our current issue


Manufacturing in the Biologics Era

Big Pharma has invested billions in the development of biologic drugs over the last five years, propelling this drug type forwards at a rapid pace (1). Indeed, by 2020, Deloitte predicts biologics will represent over a quarter of the entire pharmaceutical market (2). These are unsurprising forecasts, considering the huge potential biologic-based drugs offer patients: enabling targeted and effective treatment of chronic conditions, including diabetes, autoimmune diseases, and cancers, while minimising many of the side effects associated with small molecule drug alternatives.

Advancements that are having a hugely positive impact on human health have introduced new obstacles for biopharma organisations and trial sponsors to overcome. Shifts towards these larger and more complex molecule drugs, which, by nature, have relatively lower yields and are more expensive to develop, create pressure to systematically drive down costs without sacrificing operational efficiencies or causing negative patient impact.

Natalie Balanovsky at Almac Clinical Services (July 2019)

Keywords: Manufacturing Biologics Almac Clinical Services Just in Time Manufacturing

    View full article    |    Back to Manufacturing section

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |